ClinicalTrials.gg
RecruitingNCT06398041Updated Jun 26, 2024

Feasibility BFRT Geriatric Stroke Patients

An interventional study of Blood flow restriction training and Opinions in Stroke, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven — 4 open to participants now, 4 under way, none of them phase 3. Stroke · Universitaire Ziekenhuizen KU Leuven.

Started
2024
the only one that year
No phase
6 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven, this one is the only one that started in 2024, is one of 6 with no phase, and was the 9th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stroke by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

The focus of this interventional study is to assess the feasibility of blood flow restriction training (BFRT) in a geriatric stroke population. Patients will undergo a 4-week program of BFRT additionally to our standard physiotherapy, conducted twice weekly by experienced physiotherapists.

The main goal of the study is to assess its feasibility concerning the safety and tolerance of BFRT from a patients and therapists scope. Furthermore, the investigators want to establish the proportion of eligible individuals \& their willingness to undergo BFRT, as well as the time investment.

The feasibility of an effectiveness study and potential sample size will be evaluated aside.

Read the detailed description

Stroke is often linked to a loss in muscle strength and a decline in functioning during daily life. In the past, several studies have focused on the effects of resistance training on muscle strength in order to restore patients functioning in daily life. For optimal improvements in muscle strength, the use of high loads with few repetitions per set have been recommended, even within the geriatric population. However, the use of high load exercises in a geriatric population can often be challenging, particularly in patients who have suffered a stroke.

To counter this, blood flow restriction training (BFRT) might give some opportunities. BFRT is a relatively new technique for strength training using a cuff to compromise blood flow in combination with low loads. It is a Japanese technique from origin also known as KAATSU and has been proven to be effective in several populations, including a geriatric population.

During this study, patients will undergo 8 sessions of BFRT given by experienced physiotherapists, twice a week during a 4-week program additionally to standard physiotherapy program: the Geriatric Activation Program Pellenberg (GAPP). Each patient will undergo 1 or 2 specific predetermined exercises for the upper or lower limb, based on the individual goals.

The main goal of the study is to assess its feasibility concerning the safety and tolerance of BFRT from a patients and therapists scope. Furthermore, the investigators want to establish the proportion of eligible individuals \& their willingness to undergo BFRT, as well as the time investment.

The feasibility of an effectiveness study and potential sample size will be evaluated aside.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Geriatric patients
  • Geriatric rehabilitation
  • Blood Flow Restriction Training
  • Physiotherapy
  • Strength training
  • stroke
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

A. Patients

Inclusion Criteria patients:

  • Patients admitted to the geriatric rehabilitation unit
  • ≥ 65years old
  • Medically stable as determined by the attending physician
  • Expecting at least 5 weeks of rehabilitation
  • Diagnosis of stroke (haemorrhagic/ischemic)
  • medical research council-scores of 2-3/5 for certain muscle groups
  • Being able to understand the exercises
  • signed

Exclusion Criteria:

  • Skin lesions located at the site of the cuff
  • Cognitive impairment making it impossible to understand the exercises
  • Severe comorbidities: (Deep Venous Thrombosis; Open wounds or infected wounds; Dialysis; Cancer; Severe High Blood pressure)

B. Healthcare workers:

Inclusion Criteria

  • being physiotherapist involved in the practical application of BFRT
  • signed informed consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Patients

    Patients will undergo 8x a BFRT session and will be asked about their feelings and thoughts using a VAS an 7 points Likert Scale

    Other: Blood flow restriction training · Other: Opinions

  • Other
    Physiotherapists

    Physiotherapists involved in the practical application of BFRT will be asked about their thoughts using a 7 point Likert Scale

    Other: Opinions

Interventions

  • OtherBlood flow restriction training

    standard physiotherapy 45 minutes per day, 5 day a week (GAPP) + 2 extra sessions of blood flow restriction training

  • OtherOpinions

    Healthcare workers in the geriatric rehabilitation ward and patients will be asked on their opinions on GAPP+Care concerning blood flow restriction training

06

What researchers measure

Primary outcomes

  1. Proportion of eligible individuals and their willingness to undergo BFRT

    Number of available patients on the ward and number of eligible patients and number of patients who participate

    Time frame: 1 year

  2. Prevalence and types of Adverse events

    During the entire time frame of the study, all adverse events will be collected and sorted into different categories. Furthermore, the prevalence of this types will be calculated

    Time frame: 1 year

  3. Rate of attended sessions over the total number of sessions planned

    attended sessions over the total number of sessions planned

    Time frame: During a time frame of 1 year, this will be calculated during 4weeks/subject

  4. Visual Analog Scale for feelings of perceived pain, effort, safety and comfort

    Feelings of perceived pain, effort, safety and comfort will be scored after every trainingssession with a visual analog scale

    Time frame: During a time frame of 1 year, each subject will be asked to complete a VAS-scale after every trainingssession (8x/subject over a period of 4 weeks)

  5. Time investment

    the time needed to execute the exercises will be divided by the total time (time to prepare the patient, calibrate the cuff pressure and execute the exercises)

    Time frame: 4 weeks/subject

  6. Feasibility assessed by the physiotherapist

    Feasibility assessed by the physiotherapist using a 7point Likert Scale for an agreement with several statements and will include options: strongly disagree, disagree, somewhat disagree, either agree or disagree, somewhat agree, and agree

    Time frame: 1 year

  7. Feasibility assessed by the patients

    Feasibility assessed by the patients using a 7point Likert Scale for an agreement with several statements and will include options: strongly disagree, disagree, somewhat disagree, either agree or disagree, somewhat agree, and agree

    Time frame: During a time frame of 1 year, this will be calculated during 4weeks/subject

Secondary outcomes

  1. Muscle Strength 1

    The Medical Research Council (MRC) Scale for Muscle Strength, scores ranging from 0 to 5, with higher scores mean a better outcome

    Time frame: During a time frame of 1 year, each subject will tested at baseline and the day following the last training session (to counteract fatigue) (2 times over 5 weeks/subject)

  2. Muscle Strength 2

    Muscle strength using a handheld dynamometer (MicroFet2), with higher scores mean a better outcome

    Time frame: During a time frame of 1 year, each subject will tested at baseline and the day following the last training session (to counteract fatigue) (2 times over 5 weeks/subject)

  3. Active ROM against gravity

    the active ROM measured with goniometer, with higher scores mean a better outcome

    Time frame: During a time frame of 1 year, each subject will tested at baseline and the day following the last training session (to counteract fatigue) (2 times over 5 weeks/subject)

  4. Functional balance

    Berg Balance Scale (BBS), scores ranging from 0 to 56, with higher scores mean a better outcome

    Time frame: During a time frame of 1 year, each subject will tested at baseline and the day following the last training session (to counteract fatigue) (2 times over 5 weeks/subject)

  5. Walking speed

    10 Meter walking test (10MWT)

    Time frame: During a time frame of 1 year, each subject will tested at baseline and the day following the last training session (to counteract fatigue) (2 times over 5 weeks/subject)

07

Study locations

1 of 1 sites recruiting
  • Universitaire Ziekenhuizen Leuven, campus Pellenberg
    Pellenberg, 3212, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2025, 11 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 11 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
May 3, 2024
StartActual
May 1, 2024
Primary completionEst.
Apr 30, 2025
CompletionEst.
Oct 1, 2025
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06398041
Collaborators
KU Leuven
Responsible party
Sponsor
First posted
May 3, 2024
Start date
May 1, 2024
Primary completion
Apr 30, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Jun 26, 2024

Study contacts

Stef Gillabel, Msc
Contact
stef.gillabel@uzleuven.be
+3216344760
Jos Tournoy, MD
principal investigator · KU UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion